I anterior columna lumbalis fusion studier udviklede 0, 7% af patienterne behandlet med InductOs antistoffer sammenlignet med 0, 8% af patienterne behandlet med autogen knogletransplantat.
In anterior lumbar spine fusion studies, 0.7% of patients receiving InductOs developed antibodies vs 0.8% of patients receiving autogenous bone graft.